Sean Stoy, MD

Interventional Pulmonologist

North Memorial Health Hospital

Robbinsville, MN

LungVisionTM Trained: 2021

Background

Lung Nodule Program Timeline

Rationale for Acquiring LungVision

Accuracy: With true real-time imaging, more accurate than navigating to a virtual target with electromagnetic navigation (i.e., superDimension)

Speed: Enables visualization of actual lesion and provides real-time decision support as to how best to approach procedure and whether possible to get to lesion

Cost: Considerably less expensive than EMN on a cost-per-case basis

Adaptability: Can serve as all-in-one navigation + real-time imaging platform utilizing existing C-arms and manual bronchoscope, yet can grow with program if obtain robotics

Ease: Shallow learning curve

Clinical and Financial Impact

Based on data presented by Sean Stoy, MD at the AABIP 2023 Annual Conference. 1

Takeaway

North Memorial Health Hospital’s acquisition of LungVision™ AI-driven image guidance enabled them to:

• Grow diagnostic bronchoscopy procedural volume 73% over 2 years primarily by providing Dr. Stoy the confidence to pursue biopsy of nodules that he previously would not have felt comfortable going after

• Save $400 per-case over superDimension ($222,600 over 3 years)

• Generate $5,000 contribution margin per procedure using LungVision™ standalone for navigation and real-time imaging ($1.6M over 3 years)

• Achieve 94.5% diagnostic yield (23% over superD) in first 37 cases using LungVision™ with Ion by Intuitive

• Generate an estimated $1.3M in incremental downstream revenue for the hospital

Sources

1 Stoy, S. (2023, August 24). Understanding Your Value: How to Ask for Technology When Building an IP Program at a Community Hospital. American Association for Bronchology and Interventional Pulmonology 6th Annual Conference. Chicago, Illinois, USA. (bodyvisionmedical.com/videos/aabip-2023-lunchsymposium)

2 superDimension data based on *Mehta AC, Hood KL, Schwarz Y, Solomon SB. The Evolutional History of Electromagnetic Navigation Bronchoscopy: State of the Art. Chest. 2018 Oct;154(4):935-947.

³Estimated cost savings based on estimated superDimensio nper-case costs and actual LungVIsion™ procedural kit cost.

⁴Estimated annual cost savings based on estimate of $400 per-case savings of LungVision™ over superDimension multiplied by number of procedural volume that year.

⁵Contribution margin calculated by the physician-reported $5,000 per case contribution margin multiplied by procedural volume that year.

⁶Incremental downstream revenue based on number of additional diagnosed patients from increase in 23% diagnostic yield, assumptions that 50% of additional diagnosed patients diagnosed with cancer, 28% private payor / 72% Medicare-Medicaid payor mix, with 35% undergoing radiation therapy, 15% undergoing lung resection, 50% undergoing chemotherapy, 80% undergoing PET scans, 100% undergoing additional CT scans, and 100% undergoing pulmonary function test reimbursed at the national average for the appropriate CPT code.